Please check your internet connection and try again.
# IV Hydrocortisone for Acute Asthma
## Overview
Hydrocortisone is a short-acting synthetic corticosteroid used in acute asthma exacerbations when oral administration is not feasible or the patient is in severe respiratory distress necessitating parenteral therapy. It acts by reducing airway inflammation and modulating the immune response.
## Primary Indications
- Management of acute, severe asthma exacerbations unresponsive to initial aggressive inhaled beta-agonist and anticholinergic therapy.
- Patients unable to tolerate oral corticosteroids (e.g., severe vomiting, intubated patients).
## Adult Dosing
- **Standard Dose:** 100 mg IV every 6 to 8 hours.
- **Duration:** Typically continued until the patient can transition to oral therapy (e.g., prednisone or prednisolone) or until symptoms resolve and the patient is stable for discharge.
## Pediatric Dosing
- **Dose:** 2 to 4 mg/kg IV per dose.
- **Frequency:** Every 6 hours.
- **Maximum:** 100 mg per dose.
- *Note: Oral prednisolone/prednisone is preferred for children unless gastric intolerance exists.*
## Dose Adjustments
- **Hepatic Impairment:** Clearance may be reduced. Monitor for increased corticosteroid effects.
- **Renal Impairment:** No specific dosage adjustment required; monitor for fluid retention.
- **Elderly:** Use lowest effective dose to minimize risk of hyperglycemia, skin thinning, and neuropsychiatric effects.
## Contraindications
- Known hypersensitivity to hydrocortisone or formulation components.
- Systemic fungal infections (avoid systemic corticosteroids unless medically necessary).
- Administration of live or live-attenuated vaccines during high-dose therapy.
## Adverse Effects
- **Common:** Hyperglycemia, fluid retention, hypertension, hypokalemia.
- **Serious:** Adrenal suppression (with prolonged use), psychiatric disturbances (insomnia, mood changes, psychosis), increased susceptibility to infection, masked signs of infection.
## Key Drug Interactions
- **Fluoroquinolones:** Increased risk of tendon rupture.
- **NSAIDs:** Increased risk of gastrointestinal ulceration/bleeding.
- **Antidiabetics:** Corticosteroids may antagonize glycemic control; increase monitoring of blood glucose.
- **CYP3A4 Inhibitors/Inducers:** Hydrocortisone is a CYP3A4 substrate; adjust based on clinical response if co-administering potent modulators.
## Monitoring
- **Clinical:** Respiratory rate, oxygen saturation, work of breathing, mental status.
- **Laboratory:** Serum glucose (especially in patients with diabetes), serum potassium (monitor for hypokalemia).
- **Adverse Effects:** Blood pressure, signs of fluid overload, daily weights.
## Clinical Pearls
- **Transitioning:** Transition to oral corticosteroids as soon as the patient can tolerate them. Prolonged tapering is generally not required for short-term courses (less than 7–10 days).
- **Efficacy:** No clear clinical advantage over oral prednisone exists for systemic bioavailability; use IV only when oral route is unavailable.
- **Local Protocols:** Specific dosing intervals and transition strategies may vary by institution. Always consult your facility's asthma pathway.
***
**Disclaimer:** This information is for educational purposes and does not replace professional clinical judgment. Always verify current prescribing information, institutional protocols, and patient-specific factors before administering medication.
